Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Drew W. Rasco, Christine Peterson, Ely Benaim, Jaime R. Merchan | ||||||||||||
Title | Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b. | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.445 | ||||||||||||
Abstract Text | Journal of Clinical Oncology 35, no. 4_suppl (February 1 2017) 445-445. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RX-3117 | TV-1360|Fluorocyclopentenylcytosine|Roducitabine|RX3117 | RX-3117 (Fluorocyclopentenylcytosine) is a small molecule that disrupts normal metabolic process, leading to cell death (Journal of Clinical Oncology 35, no. 4_suppl (February 1 2017) 445-445, PMID: 32295203, PMID: 31262886). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|